Cargando…

Methotrexate (MTX) Plus Hydroxychloroquine versus MTX Plus Leflunomide in Patients with MTX-Resistant Active Rheumatoid Arthritis: A 2-Year Cohort Study in Real World

PURPOSE: To compare the efficacy, safety, and cost-effectiveness of methotrexate (MTX) plus hydroxychloroquine (HCQ) vs MTX plus leflunomide (LEF) in established rheumatoid arthritis (RA) with inadequate response to MTX monotherapy in a real-world Chinese cohort. PATIENTS AND METHODS: A prospective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Le, Chen, Fangfang, Geng, Shikai, Wang, Xiaodong, Gu, Liyang, Lang, Yitian, Li, Ting, Ye, Shuang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755368/ https://www.ncbi.nlm.nih.gov/pubmed/33376379 http://dx.doi.org/10.2147/JIR.S282249

Ejemplares similares

Treatment of methotrexate (MTX) intolerance: behavioural therapy, versus switch to parenteral MTX versus oral MTX
por: Verkaaik, M, et al.
Publicado: (2011)

GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis
por: Vieira-Sousa, Elsa, et al.
Publicado: (2020)

How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy
por: Taylor, Peter. C., et al.
Publicado: (2019)

Monocyte populations as markers of response to adalimumab plus MTX in rheumatoid arthritis
por: Chara, Luis, et al.
Publicado: (2012)

Monoclonal antibody targeting of methotrexate (MTX) against MTX-resistant tumour cell lines.
por: Affleck, K., et al.
Publicado: (1992)

Impairment of Methotrexate (MTX)‐Polyglutamate Formation of MTX‐resistant K562 Cell Lines
por: Koizumi, Shoichi
Publicado: (1988)

Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients
por: Saito, Shuntaro, et al.
Publicado: (2019)

ML-13 AN ATTEMPT OF RECHALLENGE OF HD-MTX AND MAINTENANCE THERAPY OF MTX FOR PATIENTS WITH PCNSL
por: Yamaguchi, Takashi, et al.
Publicado: (2019)

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis
por: Katchamart, W, et al.
Publicado: (2008)

Monitoring Of High-Dose Methotrexate (Mtx)-Related Toxicity and Mtx Levels in Children with Acute Lymphoblastic Leukemia: A Pilot-Study in Indonesia
por: Sari, Nur Melani, et al.
Publicado: (2021)

Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy
por: Zhang, Jing, et al.
Publicado: (2020)

AHR-dependent genes and response to MTX therapy in rheumatoid arthritis patients
por: Wajda, Anna, et al.
Publicado: (2021)

LETTER TO THE EDITOR Subcutaneous (SC) Methotrexate (MTX) is Better and Well-Tolerable than Oral MTX in Rheumatoid Arthritis Patients, Switched from Oral to SC Administration Due to Gastrointestinal Side Effects
por: Borman, Pinar, et al.
Publicado: (2014)

Implementation of an Outpatient HD-MTX Initiative
por: Sokol, Kelsey, et al.
Publicado: (2022)

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial
por: Stohl, William, et al.
Publicado: (2012)

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
por: Emery, Paul, et al.
Publicado: (2020)

Comparative Effectiveness of Combining MTX with Biologic Drug Therapy Versus Either MTX or Biologics Alone for Early Rheumatoid Arthritis in Adults: a Systematic Review and Network Meta-analysis
por: Donahue, Katrina E., et al.
Publicado: (2019)

Methotrexate (MTX) inhibition of cytokine production: relationship with clinical outcome and genetic polymorphisms
por: Sabina, P, et al.
Publicado: (2003)

Complete Genome Sequence of Serratia marcescens Phage MTx
por: Graham, Kristin, et al.
Publicado: (2019)

Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes
por: Genovese, Mark C, et al.
Publicado: (2018)

The usefulness of (18)F-FDG PET/CT for assessing methotrexate-associated lymphoproliferative disorder (MTX-LPD)
por: Watanabe, Shiro, et al.
Publicado: (2016)

Relationship Between the Free and Total Methotrexate Plasma Concentration in Children and Application to Predict the Toxicity of HD-MTX
por: Dong, Wei-Chong, et al.
Publicado: (2021)

Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study
por: Musdalita, Eva, et al.
Publicado: (2022)

Serious infections in JIA patients upon MTX, TFN inhibitors and combinations
por: Horneff, Gerd, et al.
Publicado: (2014)

Maitotoxin-4, a Novel MTX Analog Produced by Gambierdiscus excentricus
por: Pisapia, Francesco, et al.
Publicado: (2017)

Mid-board miniature dual channel optical transmitter MTx and transceiver MTRx
por: Zhao, Xiandong, et al.
Publicado: (2020)

Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients
por: Schoemaker, Casper G., et al.
Publicado: (2018)

Identification and Characterization of the Direct Interaction between Methotrexate (MTX) and High-Mobility Group Box 1 (HMGB1) Protein
por: Kuroiwa, Yuki, et al.
Publicado: (2013)

Facile Electrochemical Determination of Methotrexate (MTX) Using Glassy Carbon Electrode-Modified with Electronically Disordered NiO Nanostructures
por: Khand, Aftab A., et al.
Publicado: (2021)

MTX optimization or adding bDMARD equally improve disease activity in rheumatoid arthritis: results from the prospective study STRATEGE
por: Gaujoux-Viala, Cécile, et al.
Publicado: (2021)

MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy
por: Shiozawa, Kazuko, et al.
Publicado: (2016)

Association Between White Blood Cells at Baseline and Treatment Failure of MTX for Ectopic Pregnancy
por: Chen, Si, et al.
Publicado: (2021)

Non-persistence and non-adherence to MTX therapy in patients with rheumatoid arthritis: a retrospective cohort study based on German RA patients
por: Müller, Sabrina, et al.
Publicado: (2017)

Investigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX)
por: Hirani, SP, et al.
Publicado: (2008)

Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis
por: Shashikumar, N.S., et al.
Publicado: (2010)

Complete Remission of Methotrexate-Related Epstein-Barr-Virus-Associated Hodgkin-Like Lymphoma following Withdrawal of MTX Coupled with Clarithromycin Administration
por: Takemori, Nobuo, et al.
Publicado: (2012)

The effective threshold dose of etanercept in patients with methotrexate-resistant rheumatoid arthritis
por: Chen, Fangfang, et al.
Publicado: (2023)

Current evidence of MTX efficacy in childhood chronic uveitis: a systematic review and meta-analysis
por: Simonini, G, et al.
Publicado: (2011)

Identification of 7 Proteins in Sera of RA Patients with Potential to Predict ETA/MTX Treatment Response
por: Obry, Antoine, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_iiapk76203gjbjun5kqqgcvfur